The present invention pertains generally to the field of therapeutic
compounds, and more specifically to certain
2',4'-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds
(collectively referred to herein as "DCBP compounds"), and more
particularly to compounds selected from compounds of the following
formula and pharmaceutically acceptable salts, solvates, and hydrates
thereof: ##STR00001## wherein: n is independently 1, 2, 3, or 4; W is
independently --C(.dbd.O)--, --CH(OH)--, or --C(.dbd.NOR.sup.OX)--;
R.sup.OX is independently --H or C.sub.1-3alkyl; J is independently: --H,
--R.sup.E1, --C(.dbd.O)--R.sup.E2, --C(.dbd.O)--O--R.sup.E3,
--C(.dbd.O)--O--S(.dbd.O).sub.2OR.sup.E4,
--C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)OR.sup.E5,
--C(.dbd.O)--(CH.sub.2).sub.n--NR.sup.NE1R.sup.NE2,
--C(.dbd.O)--(CH.sub.2).sub.n--NR.sup.NE3--C(.dbd.O)R.sup.E6,
--C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)--NR.sup.NE4R.sup.NE5, or
--P(.dbd.O)(OR.sup.E7)(OR.sup.E8); wherein each of R.sup.E1, R.sup.E2,
R.sup.E3, R.sup.E4, R.sup.E5, R.sup.E6, and R.sup.E7 is independently:
--H, C.sub.1-3alkyl, -Ph, or --CH.sub.2-Ph. The present invention also
pertains to pharmaceutical compositions comprising such compounds, and
the use of such compounds and compositions, both in vitro and in vivo, in
treatment and/or prevention, for example, of inflammation and/or joint
destruction and/or bone loss; of disorders mediated by excessive and/or
inappropriate and/or prolonged activation of the immune system; of,
inflammatory and autoimmune disorders, for example, rheumatoid arthritis,
psoriasis, psoriatic arthritis, inflammatory bowel disease, ankylosing
spondylitis, and the like; of disorders associated with bone loss, such
as bone loss associated with excessive osteoclast activation in
rheumatoid arthritis, osteoporosis, cancer associated bone disease,
Paget's disease and the like.
